{"id":53615,"date":"2023-02-03T13:02:24","date_gmt":"2023-02-03T12:02:24","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/neurent-medical-announces-limited-market-release-of-neuromark-system-to-treat-chronic-rhinitis\/"},"modified":"2023-02-03T13:02:24","modified_gmt":"2023-02-03T12:02:24","slug":"neurent-medical-announces-limited-market-release-of-neuromark-system-to-treat-chronic-rhinitis","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/neurent-medical-announces-limited-market-release-of-neuromark-system-to-treat-chronic-rhinitis\/","title":{"rendered":"Neurent Medical Announces Limited Market Release of NEUROMARK\u00ae System to Treat Chronic Rhinitis"},"content":{"rendered":"
\n

\nNEUROMARK received new Category I CPT code and support from AAO position statement<\/i>\n<\/p>\n

GALWAY, Ireland–(BUSINESS WIRE)–Neurent Medical<\/a>, a company pioneering innovative non-surgical interventions to treat chronic inflammatory sino-nasal diseases, today announced its NEUROMARK\u00ae<\/sup> Rhinitis Neurolysis Therapy (RNT) is now commercially available in limited U.S. markets. Commercialization comes as the American Medical Association (AMA) issued a new Category I Current Procedural Terminology (CPT\u00ae<\/sup>) code for posterior nasal nerve ablation (PNN) procedures, which includes NEUROMARK, to treat chronic rhinitis. The code will go into effect in January 2024. Furthermore, the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) endorses this procedure<\/a>.\n<\/p>\n

<\/a><\/p>\n

\nApproximately one in four Americans suffer from chronic rhinitis1<\/sup>, which can result in irritating symptoms including rhinorrhea (runny nose), persistent congestion, swelling of the mucosal membrane in the nose, and sneezing and nasal itching caused by inflammation. NEUROMARK\u2019s unique device and intelligent technology platform enable Otolaryngologists to treat chronic rhinitis patients with precision and control and enhance the patient experience from treatment through recovery.\n<\/p>\n

\n\u201cOur goal is to provide an easy-to-operate, smart treatment that provides clinicians with more precise control and confidence, and patients with a safe, comfortable experience,\u201d said Brian Shields, CEO of Neurent Medical. \u201cThe new CPT code underscores the value of this technology as we further grow our commercial presence in the U.S. and work to make NEUROMARK more accessible to the millions of patients living with chronic rhinitis today.\u201d\n<\/p>\n

\nNEUROMARK is designed to gently apply controlled low-power radio frequency (RF) energy to target regions of the nasal cavity, disrupting the parasympathetic nerve signals that can trigger an inflammatory response. This unique system offers ENTs a novel and unique leaflet design to help deliver precision neurolysis of posterior nasal nerves, with the intelligence and flexibility to comfortably accommodate a range of anatomies.\n<\/p>\n

\nThe recent endorsement2<\/sup> of PNN by the AAO-HNS, a specialty society representing almost 12,000 ENT surgeons, further validates Neurent Medical\u2019s long-term future in the treatment of chronic rhinitis.\n<\/p>\n

\nAbout Neurent Medical<\/b>\n<\/p>\n

\nNeurent Medical is pioneering innovative treatments for chronic inflammatory sino-nasal diseases by targeting and safely disrupting hyperactive autonomic nerves that drive underlying inflammation. Its proprietary NEUROMARK\u00ae<\/sup> technology with a unique design and advanced algorithmic control, physicians can precisely target and safely disrupt multiple underlying nerve branches in a single procedure to alleviate Chronic Rhinitis symptoms and improve patient quality of life. The venture capital-backed company is headquartered in Galway, Ireland. For more information visit www.neurentmedical.com<\/a>.\n<\/p>\n

\n__________________
\n
1 Settipane RA, Charnock DR. Epidemiology of rhinitis: allergic and nonallergic. Clin Allergy Immunol. 2007;19:23-34. PMID: 17153005.
\n
2 Position Statement: PNN Ablation for the Treatment of Chronic Rhinitis. American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS). (2023, January 17).\n<\/p>\n

Contacts<\/b> <\/p>\n

\nHealth+Commerce
\n
Angela Christoforos
\n
angela@healthandcommerce.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

NEUROMARK received new Category I CPT code and support from AAO position statement GALWAY, Ireland–(BUSINESS WIRE)–Neurent Medical, a company pioneering innovative non-surgical interventions to treat chronic inflammatory sino-nasal diseases, today announced its NEUROMARK\u00ae Rhinitis Neurolysis Therapy (RNT) is now commercially available in limited U.S. markets. Commercialization comes as the American Medical Association (AMA) issued a … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-53615","6":"format-standard","7":"category-industry"},"yoast_head":"\nNeurent Medical Announces Limited Market Release of NEUROMARK\u00ae System to Treat Chronic Rhinitis - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/neurent-medical-announces-limited-market-release-of-neuromark-system-to-treat-chronic-rhinitis\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Neurent Medical Announces Limited Market Release of NEUROMARK\u00ae System to Treat Chronic Rhinitis - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"NEUROMARK received new Category I CPT code and support from AAO position statement GALWAY, Ireland–(BUSINESS WIRE)–Neurent Medical, a company pioneering innovative non-surgical interventions to treat chronic inflammatory sino-nasal diseases, today announced its NEUROMARK\u00ae Rhinitis Neurolysis Therapy (RNT) is now commercially available in limited U.S. markets. Commercialization comes as the American Medical Association (AMA) issued a ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/neurent-medical-announces-limited-market-release-of-neuromark-system-to-treat-chronic-rhinitis\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-03T12:02:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230203005078\/en\/1704527\/21\/Neurent-CMYK.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neurent-medical-announces-limited-market-release-of-neuromark-system-to-treat-chronic-rhinitis\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neurent-medical-announces-limited-market-release-of-neuromark-system-to-treat-chronic-rhinitis\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Neurent Medical Announces Limited Market Release of NEUROMARK\u00ae System to Treat Chronic Rhinitis\",\"datePublished\":\"2023-02-03T12:02:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neurent-medical-announces-limited-market-release-of-neuromark-system-to-treat-chronic-rhinitis\\\/\"},\"wordCount\":461,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neurent-medical-announces-limited-market-release-of-neuromark-system-to-treat-chronic-rhinitis\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230203005078\\\/en\\\/1704527\\\/21\\\/Neurent-CMYK.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neurent-medical-announces-limited-market-release-of-neuromark-system-to-treat-chronic-rhinitis\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neurent-medical-announces-limited-market-release-of-neuromark-system-to-treat-chronic-rhinitis\\\/\",\"name\":\"Neurent Medical Announces Limited Market Release of NEUROMARK\u00ae System to Treat Chronic Rhinitis - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neurent-medical-announces-limited-market-release-of-neuromark-system-to-treat-chronic-rhinitis\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neurent-medical-announces-limited-market-release-of-neuromark-system-to-treat-chronic-rhinitis\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230203005078\\\/en\\\/1704527\\\/21\\\/Neurent-CMYK.jpg\",\"datePublished\":\"2023-02-03T12:02:24+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neurent-medical-announces-limited-market-release-of-neuromark-system-to-treat-chronic-rhinitis\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neurent-medical-announces-limited-market-release-of-neuromark-system-to-treat-chronic-rhinitis\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neurent-medical-announces-limited-market-release-of-neuromark-system-to-treat-chronic-rhinitis\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230203005078\\\/en\\\/1704527\\\/21\\\/Neurent-CMYK.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230203005078\\\/en\\\/1704527\\\/21\\\/Neurent-CMYK.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neurent-medical-announces-limited-market-release-of-neuromark-system-to-treat-chronic-rhinitis\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Neurent Medical Announces Limited Market Release of NEUROMARK\u00ae System to Treat Chronic Rhinitis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Neurent Medical Announces Limited Market Release of NEUROMARK\u00ae System to Treat Chronic Rhinitis - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/neurent-medical-announces-limited-market-release-of-neuromark-system-to-treat-chronic-rhinitis\/","og_locale":"en_US","og_type":"article","og_title":"Neurent Medical Announces Limited Market Release of NEUROMARK\u00ae System to Treat Chronic Rhinitis - Pharma Trend","og_description":"NEUROMARK received new Category I CPT code and support from AAO position statement GALWAY, Ireland–(BUSINESS WIRE)–Neurent Medical, a company pioneering innovative non-surgical interventions to treat chronic inflammatory sino-nasal diseases, today announced its NEUROMARK\u00ae Rhinitis Neurolysis Therapy (RNT) is now commercially available in limited U.S. markets. Commercialization comes as the American Medical Association (AMA) issued a ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/neurent-medical-announces-limited-market-release-of-neuromark-system-to-treat-chronic-rhinitis\/","og_site_name":"Pharma Trend","article_published_time":"2023-02-03T12:02:24+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230203005078\/en\/1704527\/21\/Neurent-CMYK.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/neurent-medical-announces-limited-market-release-of-neuromark-system-to-treat-chronic-rhinitis\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/neurent-medical-announces-limited-market-release-of-neuromark-system-to-treat-chronic-rhinitis\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Neurent Medical Announces Limited Market Release of NEUROMARK\u00ae System to Treat Chronic Rhinitis","datePublished":"2023-02-03T12:02:24+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/neurent-medical-announces-limited-market-release-of-neuromark-system-to-treat-chronic-rhinitis\/"},"wordCount":461,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/neurent-medical-announces-limited-market-release-of-neuromark-system-to-treat-chronic-rhinitis\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230203005078\/en\/1704527\/21\/Neurent-CMYK.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/neurent-medical-announces-limited-market-release-of-neuromark-system-to-treat-chronic-rhinitis\/","url":"https:\/\/pharma-trend.com\/en\/neurent-medical-announces-limited-market-release-of-neuromark-system-to-treat-chronic-rhinitis\/","name":"Neurent Medical Announces Limited Market Release of NEUROMARK\u00ae System to Treat Chronic Rhinitis - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/neurent-medical-announces-limited-market-release-of-neuromark-system-to-treat-chronic-rhinitis\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/neurent-medical-announces-limited-market-release-of-neuromark-system-to-treat-chronic-rhinitis\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230203005078\/en\/1704527\/21\/Neurent-CMYK.jpg","datePublished":"2023-02-03T12:02:24+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/neurent-medical-announces-limited-market-release-of-neuromark-system-to-treat-chronic-rhinitis\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/neurent-medical-announces-limited-market-release-of-neuromark-system-to-treat-chronic-rhinitis\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/neurent-medical-announces-limited-market-release-of-neuromark-system-to-treat-chronic-rhinitis\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230203005078\/en\/1704527\/21\/Neurent-CMYK.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230203005078\/en\/1704527\/21\/Neurent-CMYK.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/neurent-medical-announces-limited-market-release-of-neuromark-system-to-treat-chronic-rhinitis\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Neurent Medical Announces Limited Market Release of NEUROMARK\u00ae System to Treat Chronic Rhinitis"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53615","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=53615"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53615\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=53615"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=53615"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=53615"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}